UK markets closed

Chugai Pharmaceutical Co., Ltd. (CHGCY)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
16.62+0.16 (+0.97%)
At close: 03:59PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 54.76B
Enterprise value 49.76B
Trailing P/E 26.10
Forward P/E 24.27
PEG ratio (5-yr expected) 7.36
Price/sales (ttm)8.22
Price/book (mrq)5.19
Enterprise value/revenue 0.05
Enterprise value/EBITDA 0.11

Trading information

Stock price history

Beta (5Y monthly) 0.48
52-week change 323.85%
S&P500 52-week change 322.38%
52-week high 322.61
52-week low 312.88
50-day moving average 318.61
200-day moving average 316.97

Share statistics

Avg vol (3-month) 3184.21k
Avg vol (10-day) 3119.61k
Shares outstanding 53.29B
Implied shares outstanding 63.29B
Float 8639.35M
% held by insiders 10.00%
% held by institutions 10.01%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 40.27
Forward annual dividend yield 41.62%
Trailing annual dividend rate 380.00
Trailing annual dividend yield 3486.03%
5-year average dividend yield 41.64
Payout ratio 438.83%
Dividend date 316 Sept 2019
Ex-dividend date 428 Dec 2023
Last split factor 212:1
Last split date 306 Jul 2020

Financial highlights

Currency in JPY.

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 31.50%
Operating margin (ttm)42.15%

Management effectiveness

Return on assets (ttm)15.01%
Return on equity (ttm)21.20%

Income statement

Revenue (ttm)1.04T
Revenue per share (ttm)314.86
Quarterly revenue growth (yoy)-24.10%
Gross profit (ttm)N/A
EBITDA 467.56B
Net income avi to common (ttm)326.37B
Diluted EPS (ttm)0.64
Quarterly earnings growth (yoy)1.20%

Balance sheet

Total cash (mrq)764.57B
Total cash per share (mrq)464.67
Total debt (mrq)N/A
Total debt/equity (mrq)N/A
Current ratio (mrq)5.53
Book value per share (mrq)997.97

Cash flow statement

Operating cash flow (ttm)383.09B
Levered free cash flow (ttm)287.75B